


In The Claims:

Cancel Claims 1-9 without prejudice to or disclaimer of the subject matter contained therein. A marked-up version of the claims showing the amendments is in Exhibit B.

Please add the following new claims::

Claim 10 (newly added). A composition for treatment of diseases involving angiogenesis comprising at least one 5(6)-substituted benzimidazole-2-carbamate of formula I in an amount sufficient to damage new vasculature:



wherein:

alk is an alkyl group;

X is oxygen, sulfur, sulphinyl, sulphonyl, carbonyl (CO), thiocarbonyl (CS), sulphonyloxy, NH, iminomethylene (C=NH), N-hydroxyiminomethylene, N-alkoxyiminomethylene, dialkoxymethylene, 1,3-dioxolan-2yl, 1,1-ethenyl, a group CHR³ or a bond;

R¹ is hydrogen, alkylaminocarbonyl or alkoxycarbonyl;

R² is hydrogen, alkoxycarbonyl, cyanomethyl, cyanoethyl, alkoxymethyl or acetoxymethyl;

R³ is hydrogen, hydroxy, alkoxy or amino;

A is a substituted aromatic, substituted heteroaromatic, substituted heterocycloalkyl, substituted alkyl or substituted cycloalkyl group; wherein the substituent on A is selected from

- (a) alkyl substituted by one or more of hydroxy, amino, alkylamino, dialkylamino, halogen, carboxyl, SO₃H, sulfate, phosphate, alkoxycarbonyl, aralkoxycarbonyl,

alkoxycarbonylamino, aminoalkylaminocarbonyl, alkoxy, alkylthio, cyano, nitro, isothiocyanate, aryl, heteroaryl and heterocycloalkyl; or

(b) a group Y selected from phosphate, alkylphosphate, $C(O)R^4$, $OC(O)R^4$, SO_2R^4 , $NHC(O)R^4$, $NR^5C(O)R^4$, SR^4 , $S(O)R^4$, OSO_2R^4 , $NHSO_2R^4$, $NR^5SO_2R^4$, SO_3H , CO_2H and CO_2R^5 ;

where R^4 is selected from hydrogen, R^5 , OR^5 , NHR^5 , NR^5R^6 , aryl, heteroaryl and heterocycloalkyl, such aryl, heteroaryl or heterocycloalkyl groups being optionally substituted with one or more substituents selected from alkyl, heterocycloalkyl, haloalkyl, hydroxy, nitro, cyano, amino, alkylamino, dialkylamino, halogen, carboxyl, SO_3H , sulfate and phosphate; and wherein R^5 and R^6 , which may be the same or different, are each an alkyl group substituted with one or more substituents selected from hydroxy, amino, alkylamino, dialkylamino, guanidino, halogen, carboxyl, SO_3H , sulfate, phosphate, aryl and heteroaryl; and prodrugs and pharmaceutically acceptable salts, solvates and hydrates thereof.

Claim 11 (newly added). A method for treatment or prophylaxis of a disease or condition involving angiogenesis in a mammal wherein a composition of Claim 8 is administered to said mammal in a dosage sufficient to damage new vasculature but insufficient to exhibit anti-mitotic activity.

Claim 12 (newly added). The method of Claim 11 wherein said composition is administered in the range of about 0.001 to about 100 mg/kg body weight.

Claim 13 (newly added). The method of Claim 11 wherein said composition is administered in the range of about 0.1 to about 50 mg/kg body weight.

Claim 14 (newly added). A method according to Claim 10 wherein Y is a phosphate group.

Claim 15 (newly added). A method according to Claim 10 wherein Y is NHC(O)R^4 where R^4 is a 1-aminoalkyl group.

Claim 16 (newly added). A method for treatment or prophylaxis of a solid cancerous tumor in a mammal wherein a composition of Claim 10 is administered to said mammal in a dosage sufficient to damage new vasculature but insufficient to exhibit anti-mitotic activity.

Claim 17 (newly added). The method of Claim 16 wherein said composition is administered in the range of about 0.001 to about 100 mg/kg body weight.

Claim 18 (newly added). The method of Claim 16 wherein said composition is administered in the range of about 0.1 to about 50 mg/kg body weight.

Claim 19 (newly added). A method according to Claim 11 further comprising the simultaneous or sequential administration of at least one anti-tumor substance.

Claim 20 (newly added). A method according to Claim 19 wherein said at least one anti-tumor substance comprises one or more of a mitotic inhibitor, an alkylating agent, an antimetabolite, an intercalating agent, an enzyme, a topoisomerase inhibitor, a thymidylate synthase inhibitor, a biological response modifier, an antibody, an anti-hormone, or any combination thereof.

Claim 21 (newly added). A method according to Claim 20 wherein said mitotic inhibitor comprises at least one of vinblastine, paclitaxel, docetaxel, or any combination thereof.

Claim 22 (newly added). A method according to Claim 20 wherein said alkylating agent comprises at least one of cisplatin, carboplatin, cyclophosphamide, or any combination thereof.

Claim 23 (newly added). A method according to Claim 20 wherein said antimetabolite comprises at least one of 5-fluorouracil, cytosine arabinoside, hydroxyurea, or any combination thereof.

Claim 24 (newly added). A method according to Claim 20 wherein said intercalating agent comprises at least one of adriamycin, bleomycin, or any combination thereof.

Claim 25 (newly added). A method according to Claim 20 wherein said enzyme comprises asparaginase.

Claim 26 (newly added). A method according to Claim 20 wherein said topoisomerase inhibitor comprises at least one of etoposide, topotecan, irinotecan, or any combination thereof.

Claim 27 (newly added). A method according to Claim 20 wherein said thymidylate synthase inhibitor comprises raltitrexed.

Claim 28 (newly added). A method according to Claim 20 wherein said biological response modifier comprises interferon.

Claim 29 (newly added). A method according to Claim 20 wherein said antibody comprises at least one of edrecolomab and antibodies against the EGFr, HER2 receptor or VEGF receptor, or any combination thereof.

Claim 30 (newly added). A method according to Claim 20 wherein said anti-hormone comprises tamoxifen.

Claim 31 (newly added). A method according to Claim 16 further comprising the simultaneous or sequential administration of one or more of a mitotic inhibitor, an alkylating agent, an antimetabolite, an intercalating agent, an enzyme, a topoisomerase inhibitor, a thymidylate synthase inhibitor, a biological response modifier, an antibody, an anti-hormone, or any combination thereof.

Claim 32 (newly added). A method according to Claim 31 wherein said mitotic inhibitor comprises at least one of vinblastine, paclitaxel, docetaxel, or any combination thereof.

Claim 33 (newly added). A method according to Claim 31 wherein said alkylating agent comprises at least one of cisplatin, carboplatin, cyclophosphamide, or any combination thereof.

Claim 34 (newly added). A method according to Claim 31 wherein said antimetabolite comprises at least one of 5-fluorouracil, cytosine arabinoside, hydroxyurea, or any combination thereof.

Claim 35 (newly added). A method according to Claim 31 wherein said intercalating agent comprises at least one of adriamycin, bleomycin, or any combination thereof.

Claim 36 (newly added). A method according to Claim 31 wherein said enzyme comprises asparaginase.

Claim 37 (newly added). A method according to Claim 31 wherein said topoisomerase inhibitor comprises at least one of etoposide, topotecan, irinotecan, or any combination thereof.

Claim 38 (newly added). A method according to Claim 31 wherein said thymidylate synthase inhibitor comprises raltitrexed.